Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ACAD's Cash to Debt is ranked higher than
95% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ACAD: No Debt )
ACAD' s 10-Year Cash to Debt Range
Min: 5.56   Max: 98090
Current: No Debt

5.56
98090
Equity to Asset 0.98
ACAD's Equity to Asset is ranked higher than
99% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACAD: 0.98 )
ACAD' s 10-Year Equity to Asset Range
Min: -2.13   Max: 0.98
Current: 0.98

-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
65% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
ACAD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 148.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3344.72
ACAD's Operating margin (%) is ranked higher than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ACAD: -3344.72 )
ACAD' s 10-Year Operating margin (%) Range
Min: -4212.45   Max: 35.82
Current: -3344.72

-4212.45
35.82
Net-margin (%) -3314.24
ACAD's Net-margin (%) is ranked higher than
52% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ACAD: -3314.24 )
ACAD' s 10-Year Net-margin (%) Range
Min: -4040.5   Max: 35.93
Current: -3314.24

-4040.5
35.93
ROE (%) -20.84
ACAD's ROE (%) is ranked higher than
72% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. ACAD: -20.84 )
ACAD' s 10-Year ROE (%) Range
Min: -372.67   Max: 50.99
Current: -20.84

-372.67
50.99
ROA (%) -20.07
ACAD's ROA (%) is ranked higher than
71% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ACAD: -20.07 )
ACAD' s 10-Year ROA (%) Range
Min: -99.33   Max: 39.43
Current: -20.07

-99.33
39.43
ROC (Joel Greenblatt) (%) -6614.34
ACAD's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. ACAD: -6614.34 )
ACAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -49728.57   Max: 3543.19
Current: -6614.34

-49728.57
3543.19
Revenue Growth (%) -79.10
ACAD's Revenue Growth (%) is ranked higher than
54% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ACAD: -79.10 )
ACAD' s 10-Year Revenue Growth (%) Range
Min: -79.1   Max: 73.1
Current: -79.1

-79.1
73.1
» ACAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ACAD Guru Trades in Q2 2013

Steven Cohen 201,431 sh (New)
» More
Q3 2013

ACAD Guru Trades in Q3 2013

Steven Cohen 157,825 sh (-21.65%)
» More
Q4 2013

ACAD Guru Trades in Q4 2013

Andreas Halvorsen 2,630,645 sh (New)
Steven Cohen 171,060 sh (+8.39%)
» More
Q1 2014

ACAD Guru Trades in Q1 2014

Ron Baron 492,442 sh (New)
Steven Cohen 1,153,694 sh (+574.44%)
Andreas Halvorsen 3,598,407 sh (+36.79%)
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 New Buy0.05%$21.87 - $30.1 $ 20.83-18%492442
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.70
ACAD's P/B is ranked higher than
73% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. ACAD: 5.70 )
ACAD' s 10-Year P/B Range
Min: 0.48   Max: 16.77
Current: 5.7

0.48
16.77
P/S 2512.00
ACAD's P/S is ranked higher than
61% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. ACAD: 2512.00 )
ACAD' s 10-Year P/S Range
Min: 0   Max: 2570.7
Current: 2512

0
2570.7
EV-to-EBIT -32.74
ACAD's EV-to-EBIT is ranked lower than
52% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACAD: -32.74 )
ACAD' s 10-Year EV-to-EBIT Range
Min: 0.6   Max: 6.3
Current: -32.74

0.6
6.3
Current Ratio 46.41
ACAD's Current Ratio is ranked higher than
99% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ACAD: 46.41 )
ACAD' s 10-Year Current Ratio Range
Min: 2.27   Max: 46.41
Current: 46.41

2.27
46.41
Quick Ratio 46.41
ACAD's Quick Ratio is ranked higher than
99% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ACAD: 46.41 )
ACAD' s 10-Year Quick Ratio Range
Min: 2.27   Max: 46.41
Current: 46.41

2.27
46.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.70
ACAD's Price/Net Cash is ranked higher than
90% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. ACAD: 5.70 )
ACAD' s 10-Year Price/Net Cash Range
Min: 0.69   Max: 19.49
Current: 5.7

0.69
19.49
Price/Net Current Asset Value 5.70
ACAD's Price/Net Current Asset Value is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. ACAD: 5.70 )
ACAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.69   Max: 109
Current: 5.7

0.69
109
Price/Tangible Book 5.60
ACAD's Price/Tangible Book is ranked higher than
79% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. ACAD: 5.60 )
ACAD' s 10-Year Price/Tangible Book Range
Min: 0.63   Max: 13.63
Current: 5.6

0.63
13.63
Price/DCF (Projected) 45.30
ACAD's Price/DCF (Projected) is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACAD: 45.30 )
ACAD' s 10-Year Price/DCF (Projected) Range
Min: 52.89   Max: 52.89
Current: 45.3

Price/Median PS Value 9.10
ACAD's Price/Median PS Value is ranked higher than
54% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ACAD: 9.10 )
ACAD' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 7.96
Current: 9.1

0.04
7.96
Earnings Yield (Greenblatt) 14.30
ACAD's Earnings Yield (Greenblatt) is ranked higher than
82% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ACAD: 14.30 )
ACAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 14.3   Max: 171.3
Current: 14.3

14.3
171.3
Forward Rate of Return (Yacktman) -2.22
ACAD's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. ACAD: -2.22 )
ACAD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -176   Max: -45.9
Current: -2.22

-176
-45.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DR6.Germany
ACADIA Pharmaceuticals Inc. was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. Pimavanserin is a new chemical entity that the company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. Parkinson's disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinson's disease. The company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimer's disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA' and 'R-SAT' are company's registered trademarks. The company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.
» More Articles for ACAD

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
comment on ACAD Mar 02 2013 
ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 05 2009 
ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009 Jul 29 2009 
ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
[video] Who's afraid of Janet Yellen? Jul 24 2014
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief... Jul 15 2014
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 15 2014
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief... Jul 15 2014
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2014
Investors Grab Acadia Pharmaceuticals 30% Cheaper Than Its Secondary Stock Offering Jun 04 2014
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014 May 27 2014
ACADIA initiated with an Overweight at JPMorgan May 15 2014
ACADIA PHARMACEUTICALS INC Financials May 14 2014
Acadia Remains On Track With Pimavanserin Program May 07 2014
ACADIA Pharmaceuticals' (ACAD) CEO Uli Hacksell on Q1 2014 Results - Earnings Call Transcript May 06 2014
ACADIA Pharmaceuticals Earnings Call scheduled for 5:00 pm ET today May 06 2014
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 06 2014
ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results May 06 2014
Q1 2014 ACADIA Pharmaceuticals Earnings Release - After Market Close May 06 2014
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences May 01 2014
ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014 Apr 29 2014
Oncology Treatments Retain Pricing Power: A Wall Street Transcript Interview with Boris Peaker,... Apr 28 2014
Wall Street Transcript Interview with Bernd Liesenfeld, the President of Quick-Med Technologies,... Apr 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide